Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy

被引：18

作者：

Shuai, Yanjie ^{[1
]}

Ma, Li ^{[1
]}

机构：

[1] Hebei Med Univ, Affiliated Hosp 4, Hebei Prov Tumor Hosp, Shijiazhuang, Hebei, Peoples R China

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2019年 / 215卷 / 01期

关键词：

Neoadjuvant chemotherapy; Estrogen receptor; Progesterone receptor; Human epidermal growth factor receptor 2; Ki67; Pathologic complete response; Prognosis; HORMONE-RECEPTOR STATUS; PRIMARY SYSTEMIC THERAPY; CORE NEEDLE-BIOPSY; NODE METASTASES; OPEN-LABEL; TRASTUZUMAB; TUMOR; SURVIVAL; MULTICENTER; DOXORUBICIN;

D O I：

10.1016/j.prp.2018.11.003

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Neoadjuvant chemotherapy(NCT) has become the standard treatment for breast cancer. The information about the tumor's sensitivity to chemotherapy and prognostic significance based on response to therapy can be provided after individualized neoadjuvant treatment The biomarkers are key factors in the decision-making process regarding treatment as well as important prognostic indicators. Studies have shown that patients who achieve pathological complete response(pCR) after NCT have a better prognosis. For patients who do not achieve pCR, the pathological characteristics of the residual tumor can make an effect on the survival. Furthermore, the immunohistochemical (IHC) markers of the residual diseases after primary systemic therapy might be different from the primary tumor. Estrogen receptor (ER), progesterone receptor (PR), and Ki67 can usually change after NCT, while human epidermal growth factor receptor 2(HER2) seems to be more stable. The relationship between changes in breast cancer molecular biomarkers and the prognosis after neoadjuvant therapy is not yet clear. The article will make a review about it.

引用

页码：29 / 33

页数：5

共 43 条

[1] Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy [J].

Acs, Balazs ;

Zambo, Veronika ;

Vizkeleti, Laura ;

Szazs, A. Marcell ;

Madaras, Lilla ;

Szentmartoni, Gyongyver ;

Tokes, Timea ;

Molnar, Bela A. ;

Molnar, Istvan Artur ;

Vari-Kakas, Stefan ;

Kulka, Janina ;

Tokes, Anna-Maria .

DIAGNOSTIC PATHOLOGY, 2017, 12 :1-12

[2] High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer (vol 21, pg 150, 2016) [J].

Alba, Emilio ;

Lluch, Ana ;

Ribelles, Nuria ;

Anton-Torres, Antonio ;

Sanchez-Rovira, Pedro ;

Albanell, Joan ;

Calvo, Lourdes ;

Garcia-Asenjo, Jose Antonio Lopez ;

Palacios, Jose ;

Chacon, Jose Ignacio ;

Ruiz, Amparo ;

De la Haba-Rodriguez, Juan ;

Segui-Palmer, Miguel A. ;

Cirauqui, Beatriz ;

Margeli, Mireia ;

Plazaola, Arrate ;

Barnadas, Agusti ;

Casas, Maribel ;

Caballero, Rosalia ;

Carrasco, Eva ;

Rojo, Federico .

ONCOLOGIST, 2016, 21 (06) :778-778

[3] Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) [J].

Arnedos, M. ;

Nerurkar, A. ;

Osin, P. ;

A'Hern, R. ;

Smith, I. E. ;

Dowsett, M. .

ANNALS OF ONCOLOGY, 2009, 20 (12) :1948-1952

[4] Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy [J].

Azevedo Koike Folgueira, Maria Aparecida ;

Brentani, Helena ;

Carraro, Dirce Maria ;

Barros Filho, Mateus De Camargo ;

Hirata Katayama, Maria Lucia ;

Santana De Abreu, Ana Paula ;

Barbosa, Edson Mantovani ;

De Oliveira, Celia Tosello ;

Patrao, Diogo F. C. ;

Mota, Louise D. ;

Netto, Mario Mourao ;

Figaro Caldeira, Jose Roberto ;

Brentani, Maria Mitzi .

ONCOLOGY REPORTS, 2009, 22 (04) :805-813

[5] Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study [J].

Balmativola, D. ;

Marchio, C. ;

Maule, M. ;

Chiusa, L. ;

Annaratone, L. ;

Maletta, F. ;

Montemurro, F. ;

Kulka, J. ;

Figueiredo, P. ;

Varga, Z. ;

Liepniece-Karele, I. ;

Cserni, G. ;

Arkoumani, E. ;

Amendoeira, I. ;

Callagy, G. ;

Reiner-Concin, A. ;

Cordoba, A. ;

Bianchi, S. ;

Decker, T. ;

Glaeser, D. ;

Focke, C. ;

van Diest, P. ;

Grabau, D. ;

Lips, E. ;

Wesseling, J. ;

Arisio, R. ;

Medico, E. ;

Wells, C. ;

Sapino, A. .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (03) :511-523

[6] Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial [J].

Bonnefoi, H. ;

Litiere, S. ;

Piccart, M. ;

MacGrogan, G. ;

Fumoleau, P. ;

Brain, E. ;

Petit, T. ;

Rouanet, P. ;

Jassem, J. ;

Moldovan, C. ;

Bodmer, A. ;

Zaman, K. ;

Cufer, T. ;

Campone, M. ;

Luporsi, E. ;

Malmstrom, P. ;

Werutsky, G. ;

Bogaerts, J. ;

Bergh, J. ;

Cameron, D. A. .

ANNALS OF ONCOLOGY, 2014, 25 (06) :1128-1136

[7] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[8] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J].

de Azambuja, Evandro ;

Holmes, Andrew P. ;

Piccart-Gebhart, Martine ;

Holmes, Eileen ;

Di Cosimo, Serena ;

Swaby, Ramona F. ;

Untch, Michael ;

Jackisch, Christian ;

Lang, Istvan ;

Smith, Ian ;

Boyle, Frances ;

Xu, Binghe ;

Barrios, Carlos H. ;

Perez, Edith A. ;

Azim, Hatem A., Jr. ;

Kim, Sung-Bae ;

Kuemmel, Sherko ;

Huang, Chiun-Sheng ;

Vuylsteke, Peter ;

Hsieh, Ruey-Kuen ;

Gorbunova, Vera ;

Eniu, Alexandru ;

Dreosti, Lydia ;

Tavartkiladze, Natalia ;

Gelber, Richard D. ;

Eidtmann, Holger ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (10) :1137-1146

[9] Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment [J].

Fasching, Peter A. ;

Heusinger, Katharina ;

Haeberle, Lothar ;

Niklos, Melitta ;

Hein, Alexander ;

Bayer, Christian M. ;

Rauh, Claudia ;

Schulz-Wendtland, Ruediger ;

Bani, Mayada R. ;

Schrauder, Michael ;

Kahmann, Laura ;

Lux, Michael P. ;

Strehl, Johanna D. ;

Hartmann, Arndt ;

Dimmler, Arno ;

Beckmann, Matthias W. ;

Wachter, David L. .

BMC CANCER, 2011, 11

[10] Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients [J].

Ge, Wen-kai ;

Yang, Ben ;

Zuo, Wen-shu ;

Zheng, Gang ;

Dai, Ying-qi ;

Han, Chao ;

Yang, Li ;

Zheng, Mei-zhu .

THORACIC CANCER, 2015, 6 (01) :64-69

← 1 2 3 4 5 →